Apollomics, Inc. (APLM)

NCM – Real Time Price. Currency in USD

14.30

+0.61 (4.42%)

At close: Jun 12, 2026, 4:00 PM EDT

13.88

-0.43 (-2.99%)

Pre-market: Jun 15, 2026, 4:00 AM EDT

27.04.2026

Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress

Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential. To date, more than 600 patients and 170 healthy volunteers have been dosed with vebreltinib in clinical trials.

01.04.2026

Apollomics Inc. Announces $2.0 Million Bridge Financing

FOSTER CITY, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), today announced that it has entered into a $2.0 million unsecured Convertible Promissory Note (the “Note”) with Mr.

22.12.2025

Apollomics Reports First Half 2025 Financial Results

FOSTER CITY, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced financial results for the first half of 2025 ended June 30, 2025.

19.11.2025

Apollomics Announces Settlement of Cayman Litigation

FOSTER CITY, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”) (Nasdaq: APLM) announced today entering into a settlement agreement (the “Settlement Agreement” or the “Agreement”) with TWVC Goldlink Partners Investment Limited and TWVC Panglin Group Investment Limited (together, “TWVC”), entities represented by Triwise Capital Management Ltd, in connection with the litigation previously filed in the Grand Court of the Cayman Islands (the “Cayman Litigation”).

18.11.2025

Apollomics Announces Changes to its Board of Directors and Composition of Committees

FOSTER CITY, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California-based late-stage clinical biopharmaceutical company, today announced the following update regarding changes to the Company's board of directors (“Board”) and composition of committees.

Videos

No Data

There is no data to display

Press releases

27.04.2026

Apollomics, Inc. (APLM)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Apollomics, Inc. (APLM)

Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress

Apollomics Inc. Announces $2.0 Million Bridge Financing

Apollomics Reports First Half 2025 Financial Results

Apollomics Announces Settlement of Cayman Litigation

Apollomics Announces Changes to its Board of Directors and Composition of Committees

Videos

No Data

Press releases

Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress

Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress

Apollomics Inc. Announces $2.0 Million Bridge Financing

Apollomics Reports First Half 2025 Financial Results

Apollomics Announces Settlement of Cayman Litigation

Apollomics Announces Changes to its Board of Directors and Composition of Committees

Videos

No Data

Press releases

Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress

Apollomics Inc. Announces $2.0 Million Bridge Financing

Apollomics Reports First Half 2025 Financial Results

Apollomics Announces Settlement of Cayman Litigation

Search stocks

Apollomics, Inc. (APLM)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Apollomics, Inc. (APLM)

Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress

Apollomics Inc. Announces $2.0 Million Bridge Financing

Apollomics Reports First Half 2025 Financial Results

Apollomics Announces Settlement of Cayman Litigation

Apollomics Announces Changes to its Board of Directors and Composition of Committees

Videos

No Data

Press releases

Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress

Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress

Apollomics Inc. Announces $2.0 Million Bridge Financing

Apollomics Reports First Half 2025 Financial Results

Apollomics Announces Settlement of Cayman Litigation

Apollomics Announces Changes to its Board of Directors and Composition of Committees

Videos

No Data

Press releases

Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress

Apollomics Inc. Announces $2.0 Million Bridge Financing

Apollomics Reports First Half 2025 Financial Results

Apollomics Announces Settlement of Cayman Litigation